1361644-26-9

中文名称 ALDOXORUBICIN

英文名称 INNO206

CAS 1361644-26-9

分子式 C37H42N4O13

分子量 750.75

MOL 文件 1361644-26-9.mol

更新日期 2024/11/15 18:20:30

1361644-26-9 结构式

基本信息物理化学性质安全数据 ALDOXORUBICIN价格(试剂级) 常见问题列表

基本信息

中文别名

(E)-N'-[1-[(2S,4S)-4-[[(2R,4S,5S,6S)-4-氨基-5-羟基-6-甲基-2-四氢吡喃基]氧基]-2,5,12-三羟基-7-甲氧基-6,11-二氧代-1,2,3,4,6,11-六氢-2-并四苯基]-2-羟基亚乙基]-6-(2,5-二氧代-2,5-二氢-1-吡咯基)己酰肼

英文别名

Aldoxorubicin
Aldoxorubicin (INNO-206)
Aldoxorubicin Aldoxorubicin
N-[(E)-[1-[(2S,4S)-4-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-hydroxyethylidene]amino]-6-(2,5-dioxopyrrol-1-yl)hexanamide
1H-Pyrrole-1-hexanoic acid, 2,5-dihydro-2,5-dioxo-, (2E)-2-[1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-hydroxyethylidene]hydrazide
(E)-N’-[1-[(2S,4S)-4-[[(2R,4S,5S,6S)-4-Amino-5-hydroxy-6-methyl-2-tetrahydropyranyl]oxy]-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-2-tetracenyl]-2-hydroxyethylidene]-6-(2,5-dioxo-2,5-dihydro-1-pyrrolyl)hexanehydrazide

物理化学性质

密度1.60±0.1 g/cm3(Predicted)

储存条件-80°, stored under nitrogen,unstable in solution, ready to use.

溶解度DMSO : 75 mg/mL (99.90 mM)

酸度系数(pKa)7.36±0.60(Predicted)

形态Solid

颜色Purple to purplish red

安全数据

危险性符号(GHS) GHS hazard pictograms

GHS08

警示词危险

危险性描述H340-H350-H360

ALDOXORUBICIN价格(试剂级)

报价日期	产品编号	产品名称	CAS号	包装	价格
2024/11/08	HY-16261	ALDOXORUBICIN Aldoxorubicin	1361644-26-9	2mg	750元
2024/11/08	HY-16261	ALDOXORUBICIN Aldoxorubicin	1361644-26-9	5mg	1200元
2024/11/08	HY-16261	ALDOXORUBICIN Aldoxorubicin	1361644-26-9	10mg	1740元

常见问题列表

生物活性

Aldoxorubicin (INNO-206) 是多柔比星 (DNA 拓扑异构酶 II 抑制剂) 的白蛋白结合前药，在酸性条件下从白蛋白中释放出来。 Aldoxorubicin (INNO-206) 在各种癌细胞系和小鼠肿瘤模型中具有有效的抗肿瘤活性。

靶点

Topoisomerase II

Daunorubicins/Doxorubicins

体外研究

Aldoxorubicin (INNO-206) (0.27 to 2.16 μM) inhibits blood vessel formation and reduces multiple myeloma cell growth in a pH-dependent fashion.

体内研究

Aldoxorubicin (INNO-206) (10.8 mg/kg, i.v.) shows significantly smaller tumor volumes and IgG levels on days 28, and is well tolerated with 90% of mice surviving until the termination of the study in the mice bearing the LAGκ-1A tumor. Aldoxorubicin (INNO-206) shows a good safety profile at doses up to 260 mg/mL doxorubicin equivalents, and is able to induce tumor regressions in breast cancer, small cell lung cancer and sarcoma in phase I study. Aldoxorubicin (INNO-206) shows superior activity over doxorubicin in a murine renal cell carcinoma model and in breast carcinoma xenograft models.